These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 10367790)
1. Phase II trial of high-dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA Am J Hematol; 1999 Jun; 61(2):115-9. PubMed ID: 10367790 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Gertz MA; Lacy MQ; Lust JA; Greipp PR; Witzig TE; Kyle RA Med Oncol; 1999 Jul; 16(2):104-9. PubMed ID: 10456658 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of recombinant interferon alfa-2 in the treatment of primary systemic amyloidosis. Gertz MA; Kyle RA Am J Hematol; 1993 Oct; 44(2):125-8. PubMed ID: 8266917 [TBL] [Abstract][Full Text] [Related]
4. A phase II trial of lenalidomide, dexamethasone and cyclophosphamide for newly diagnosed patients with systemic immunoglobulin light chain amyloidosis. Cibeira MT; Oriol A; Lahuerta JJ; Mateos MV; de la Rubia J; Hernández MT; Granell M; Fernández de Larrea C; San Miguel JF; Bladé J; Br J Haematol; 2015 Sep; 170(6):804-13. PubMed ID: 25974382 [TBL] [Abstract][Full Text] [Related]
5. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis. Sanchorawala V; Seldin DC; Berk JL; Sloan JM; Doros G; Skinner M Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):469-72. PubMed ID: 21156464 [TBL] [Abstract][Full Text] [Related]
6. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study. Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082 [TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Kastritis E; Roussou M; Gavriatopoulou M; Migkou M; Kalapanida D; Pamboucas C; Kaldara E; Ntalianis A; Psimenou E; Toumanidis ST; Tasidou A; Terpos E; Dimopoulos MA Am J Hematol; 2015 Apr; 90(4):E60-5. PubMed ID: 25580702 [TBL] [Abstract][Full Text] [Related]
8. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Dispenzieri A; Buadi F; Laumann K; LaPlant B; Hayman SR; Kumar SK; Dingli D; Zeldenrust SR; Mikhael JR; Hall R; Rajkumar SV; Reeder C; Fonseca R; Bergsagel PL; Stewart AK; Roy V; Witzig TE; Lust JA; Russell SJ; Gertz MA; Lacy MQ Blood; 2012 Jun; 119(23):5397-404. PubMed ID: 22493299 [TBL] [Abstract][Full Text] [Related]
13. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP; N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669 [TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment. Gertz MA Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896 [TBL] [Abstract][Full Text] [Related]
15. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357 [TBL] [Abstract][Full Text] [Related]
16. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Bochtler T; Hegenbart U; Kunz C; Benner A; Seckinger A; Dietrich S; Granzow M; Neben K; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO Amyloid; 2014 Mar; 21(1):9-17. PubMed ID: 24455967 [TBL] [Abstract][Full Text] [Related]
17. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088 [TBL] [Abstract][Full Text] [Related]
18. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. Mahmood S; Venner CP; Sachchithanantham S; Lane T; Rannigan L; Foard D; Pinney JH; Gibbs SD; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD Br J Haematol; 2014 Sep; 166(6):842-8. PubMed ID: 24930361 [TBL] [Abstract][Full Text] [Related]
19. [Current treatment of AL amyloidosis]. Desport E; Moumas E; Abraham J; Delbès S; Lacotte-Thierry L; Touchard G; Fermand JP; Bridoux F; Jaccard A Nephrol Ther; 2011 Nov; 7(6):467-73. PubMed ID: 21497573 [TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Gertz MA Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]